Researcher Spotlight: Samuel Yamshon, MD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY The lymphoma treatment landscape has been dramatically changed in recent years with the development of novel immunotherapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies. Dr.…
Researcher Spotlight: Timothy Voorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Post-transplant lymphoproliferative disorders (PTLDs) are aggressive forms of lymphoma that develop after a solid organ transplant, often due to reactivation of the Epstein-Barr virus (EBV) following the use…
Researcher Spotlight: Harsh Shah, DO The University of Utah Immunotherapy with checkpoint inhibitors is commonly used for treatment of Hodgkin lymphoma after relapse. While many patients initially respond to these therapies, the development of resistance is common over time. Dr.…
Researcher Spotlight: Niloufer Khan, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Health Equity Initiative Cutaneous T-cell lymphoma (CTCL) is a chronic form of cancer that causes pain, discomfort, and itchiness that can affect patients’ well-being and quality of life. “Itch…
Researcher Spotlight: Tomohiro Aoki, MD, PhD UNIVERSITY HEALTH NETWORK Peykoff Initiative Investigator Cancer cells exist within a greater tumor microenvironment that is modified by tumor cells to support their growth and proliferation. These cells can also modify their environment to…
Researcher Spotlight: Erin Parry, MD, PhD DANA-FARBER CANCER INSTITUTE Dr. Parry’s research is centered at the intersection of genomics and cancer immunotherapy, with a focus on B cell lymphomas. Her LRF research project is aimed at understanding the processes that…
Researcher Spotlight: Andrew Jallouk, MD, PhD Vanderbilt University Medical Center Errol M. Cook Memorial Scholar Chimeric antigen receptor (CAR) T-cell therapy represents a highly effective treatment option for many types of lymphoma. Currently available CAR T-cell therapies are engineered on…
Researcher Spotlight: Alexander Boardman, MD Memorial Sloan Kettering Dobosh Family Scholar Treatment of lymphoma has been revolutionized by the emergence of CD19-directed chimeric antigen receptor (CAR) T-cell therapies, but many patients still relapse after treatment. Dr. Boardman’s LRF research seeks…
Researcher Spotlight: Ajilan Al Zaki, MD, PhD MD Anderson Cancer Center Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by inflammation. In some…
Researcher Spotlight: Timothy Voorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Schroder Family Scholar Post-transplant lymphoproliferative disorders (PTLD) are an aggressive group of lymphomas that occur in the setting of immunosuppression after solid organ transplant. There are very few…
